MedTrace Logo

Reduction of Pathogen Load From the Blood in Septic Patients With Suspected, Life-threatening Bloodstream Infection

NCT04260789 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 232

Last updated 2021-12-17

No results posted yet for this study

Summary

Safety and Performance Evaluation of Seraph 100 Microbind Affinity Blood Filter (Seraph 100) in the reduction of pathogen load from the blood in septic patients with suspected, life-threatening bloodstream infection

Conditions

  • Bloodstream Infection

Interventions

DEVICE

Seraph 100,The Microbind Affinity Blood Filter

Treatment with Seraph 100 in one arm

Sponsors & Collaborators

  • ExThera Medical Corporation

    collaborator INDUSTRY

  • Vivantes Clinic Neukölln

    collaborator OTHER

  • ExThera Medical Europe BV

    lead INDUSTRY

Principal Investigators

  • Herwig Gerlach, Prof. · Vivantes Clinic Neukölln

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-19
Primary Completion
2022-03-01
Completion
2022-08-01

Countries

  • Austria
  • Belgium
  • France
  • Germany
  • Italy
  • Netherlands
  • Poland
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04260789 on ClinicalTrials.gov